{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The number of participants with ≥1 AE is reported. An AE is any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study product(s), whether or not considered related to the use of the product(s).","groups":[{"description":"Participants undergo ≤3 successive 21-day treatment cycles. During Cycle 1, participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.3 mg/m\\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 2 participants receive vorinostat (400 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\\^2 IV on Days 1, 4, 8, and 11). If that dose is not well tolerated, during Cycle 3 participants receive vorinostat (300 mg QD on Days 1 through 14) + bortezomib (1.0 mg/m\\^2 IV on Days 1, 4, 8, and 11).","id":"OG000","title":"Vorinostat + Bortezomib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants are included.","reportingStatus":"POSTED","timeFrame":"Up to 346 days (up to 30 days after the final dose of study treatment)","title":"Number of Participants With an Adverse Event (AE)","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}